HC Wainwright & Co. Reiterates Buy on IN8bio, Maintains $14 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on IN8bio (NASDAQ:INAB) and maintained a $14 price target on the company's stock.
November 13, 2023 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating and a $14 price target for IN8bio, indicating a positive outlook for the stock.
The reiteration of a Buy rating and the maintenance of a $14 price target by a reputable analyst could lead to increased investor confidence and a potential short-term uplift in IN8bio's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100